Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients1, yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3. Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine
Neoantigens arise from somatic mutations that differ from wild-type antigens and are specific to each individual patient, which provide tumor specific targets for developing personalized cancer vaccines. Decades of work has increasingly shown the potential of targeting neoantigens to generate effective ...
neoantigensimmunotherapycancer vaccinesRindopepimutprecision medicineIntroduction : Glioblastoma multiforme (GBM) is the most prevalent primary brain tumor. In spite of the rigorous multimodal treatment involving surgery and radiochemotherapy, GBM has a dismal prognosis and rapid relapsing potential. Hence, ...
The recent success of cancer immunotherapies has highlighted the benefit of harnessing the immune system for cancer treatment. Vaccines have a long history of promoting immunity to pathogens and, consequently, vaccines targeting cancer neoantigens have b
Abstract Title: “Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer” Abstract Number:CT025 Date: Sunday, April 7, 2024 Time: 3:00 PM - 5:00 PM PST Posters Candidate: BNT116 Session Title:Phase I Clinic...
“Several studies have shown neoantigen vaccines are feasible, safe and have promising clinical activity in patients with high TMB tumors in both metastatic and adjuvant settings.” According to the authors, there are various clinical trials assessing the potential of neoantigen-based cancer vaccines,...
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer 2023, Nature Combination strategies with PD-1/PD-L1 blockade: current advances and future directions 2022, Molecular Cancer Therapeutic cancer vaccines 2021, Nature Reviews Cancer Advances in the development of personalized neoantige...
The vaccine was given with the immunostimulant, or adjuvant, poly-ICLC, which is “a synthetic, stabilized, double-stranded RNA capable of activating multiple innate immune receptors, making it the optimal adjuvant for inducing immune responses against tumor neoantigens,” said Nina Bhardwaj, Director...
标题(英文):Listeria monocytogenes personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens 标题(中文):李斯特菌个体化肿瘤疫苗驱动肿瘤新抗原的免疫治疗 发表期刊:bioRxiv 作者单位:Amgen公司 发表年份:2020 文章地址:https://doi.org/10.1101/2020.05.11.088930 ...
Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine APC-binding molecules with the delivery of personalized tumor antigens holds the potential to improve the clinical efficacy of therapeutic DNA cancer vaccines... M Barrio-Calvo,S...